4-HO-MiPT - PsychonautWiki

4-HO-MiPT

Summary sheet: 4-HO-MiPT
4-HO-MiPT
4-HO-MiPT.svg
Chemical Nomenclature
Common names 4-HO-MiPT, Miprocin
Substitutive name 4-Hydroxy-N-methyl-N-isopropyltryptamine
Systematic name 3-(2-[Isopropyl (methyl) amino]ethyl)-1H-indol-4-ol
Class Membership
Psychoactive class Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



⇣ Oral
Dosage
Threshold 5 mg
Light 10 - 15 mg
Common 15 - 25 mg
Strong 25 - 35 mg
Heavy 35 mg +
Duration
Total 4 - 6 hours
Onset 15 - 45 minutes
Come up 20 - 60 minutes
Peak 1.5 - 2.5 hours
Offset 1 - 2 hours
After effects 2 - 12 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Cannabis
Stimulants
Tramadol
Lithium


4-Hydroxy-N-methyl-N-isopropyltryptamine (also known as 4-HO-MiPT, and Miprocin) is a novel psychedelic substance of the tryptamine class that produces psilocybin-like psychedelic effects when administered. It is part of a series of psychedelic substituted tryptamines such as 4-AcO-DMT, 4-HO-MET, 4-HO-DiPT that are considered to produce variations of the core psychedelic effects typified by psilocin.

This substance is relatively uncommon and has only a short history of human use. Alexander Shulgin evaluated its activity in humans in 1979, describing a trial of 12mg as a richly insightful and highly erotic experience.[1] A description of 4-HO-MiPT is included in Shulgin's 1997 book TiHKAL.[2] Shulgin's trials and other anecdotal reports suggest that 4-HO-MiPT is similar in activity to psilocin, the active component in psilocybin mushrooms.

Very little data exists about the pharmacological properties, metabolism, and toxicity of 4-HO-MiPT in humans. As with psilocin, there have been no reported deaths from 4-HO-MiPT use despite the existence of reports of people taking doses which far exceeds the active dose. This suggests that it is well-tolerated physiologically.[citation needed]

Today, 4-HO-MiPT is either used recreationally or as an entheogenic substance and is typically distributed as a grey-area research chemical by online vendors.

History and culture

 

This History and culture section is a stub.

As a result, it may contain incomplete or wrong information. You can help by expanding it.

The first synthesis of 4-HO-MiPT was published in 1981 by a team of chemists led by David Repke.[3] Repke and Shulgin later collaborated on a paper evaluating the effects of different oxygen substituents on the MiPT structure, describing 4-HO-MiPT as the most interesting of the series and the only one to possess classical hallucinogen effects.[4]

Chemistry

 
Generic structure of a tryptamine molecule.

4-HO-MiPT or 4-hydroxy-N-methyl-N-isopropyltryptamine is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 4-HO-MiPT is substituted at R4 of its indole heterocycle with a hydroxyl (HO) functional group OH-. It also contains a methyl group and an isopropyl chain bound to the terminal amine RN of its tryptamine backbone (MiPT). 4-HO-MiPT is the N-substituted isopropyl homologue of 4-HO-DMT (Psilocin).[2]

Pharmacology

Further information: Serotonergic psychedelic

4-HO-MiPT's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive. 4-HO-MiPT is thought to be a serotonergic psychedelic. Like other serotonergic psychedelics, its method of action is believed to result from its partial agonism of 5-HT2A and 5-HT1A serotonin receptors.[5]

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects
 

    • Sedation & Stimulation - 4-HO-MiPT is considered have the paradoxical property of both being relaxing, stoning and mildly sedating with a marked sense of physical stimulation that distinguishes it from related substances like psilocybin mushrooms or 4-AcO-DMT.
    • Spontaneous physical sensations - The "body high" of 4-HO-MiPT can be described as a pleasurable, warm, soft, and all-encompassing tingling sensation. This maintains a consistent presence that steadily rises following the onset and hits its limit once the peak has been reached.
    • Changes in felt bodily form - This effect is often accompanied by a sense of warmth or psychophysical unity and usually occurs around or directly after the peak of the experience. Users can feel as if they are physically part of or conjoined with other objects in a seamless continuity. This is usually reported as feeling comfortable, tranquil and mindful, though it can also manifest in the form of bodily tension.
    • Changes in felt gravity
    • Pain relief - This effect is distinct from pain relief produced by opioids. It appears to manifest itself as a result of changes in how the user perceives their body, rather than direct suppression of pain.
    • Nausea - This effect can be greatly lessened or even completely avoided if the individual has an empty stomach prior to ingestion. It is sometimes recommended that one either refrain from eating for approximately 6 to 8 hours before-hand, or to eat a light meal 3 to 4 hours before if the user is feeling physically fatigued and undernourished. The nausea produced by 4-HO-MiPT is generally considered to be much less prominent than it is with psilocybin mushrooms, perhaps owing to the fact that there is no fungal-matter the body has to digest when the isolated synthetic form is consumed.
    • Temperature regulation suppression - 4-HO-MiPT can cause fluctuates in the user's internal sense of temperature, which can manifest as sudden bouts of uncomfortable coldness or warmth, which is why a climate-controllable environment is strongly recommended in terms of a proper setting for a trip.
    • Muscle contractions - The muscle contractions that can occasionally be produced by 4-HO-MiPT tend to be transient and benign feeling in nature, compared to many other tryptamines, phenethylamines and lysergamides.
    • Olfactory hallucination
    • Frequent urination
    • Pupil dilation
    • Increased salivation
    • Excessive yawning - This effect seems to be uniquely pronounced among psilocin and related tryptamines. It can occur to a lesser degree on LSD and very rarely on psychedelic phenethylamines like mescaline. It typically occurs in conjunction with watery eyes.
    • Watery eyes
    • Teeth grinding - This component is considerably less intense when compared with that of substances like MDMA when it does happen to occur, but happens more readily than with related substances like psilocin or psilocybin, perhaps owing to the greater degree of stimulation it produces.
    • Seizure[citation needed] - This is a likely a rare effect but may occur for those who are predisposed to them, especially while in physically taxing conditions such as being dehydrated, fatigued, undernourished, or overheated. However it should be noted that there are no documented cases of seizures occurring with this compound.

Visual effects
 

Cognitive effects
 

Auditory effects
 

Multi-sensory effects
 

    • Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.

Transpersonal effects
 

Combination effects

  • Cannabis - Cannabis majorly amplifies the sensory and cognitive effects of 4-HO-MiPT. This should be used with extreme caution, especially if one is not experienced with psychedelics. This interaction can also amplify the anxiety, confusion and delusion producing aspects of cannabis significantly. Those who choose to use this combination are advised to start off with only a fraction of their usual cannabis dose, and slow down the pace of their normal intake considerably.
  • Dissociatives - Dissociatives can enhance the geometry, euphoria, dissociation and hallucinatory effects of 4-HO-MiPT. Dissociative-induced holes, spaces, and voids while under the influence of 4-HO-MiPT can result in significantly more vivid visuals than dissociatives alone, along with more intense internal hallucinations, confusion, nausea, delusions and chances of a psychotic reaction.
  • Benzodiazepines - Depending on the dosage, benzodiazepines can slightly to completely reduce the intensity of the cognitive, physical and visual effects of a miprocin trip. They can be very efficient at largely stopping or mitigating a bad trip at the cost of amnesia and reduced trip intensity. Caution is advised when acquiring them for this purpose, however, due to the very high addiction potential that benzodiazepines possess.
  • Psychedelics - When used in combination with other psychedelics, the physical, cognitive and visual effects of each substance intensify and synergize strongly with each other. The synergy between those substances is unpredictable, and for this reason, is generally not advised. If choosing to combine psychedelics, it is recommended to start with lower dosages than one would take for either substance individually.

Experience reports

There are currently anecdotal reports which describe the effects of this compound within our experience index.

Additional experience reports can be found here:

Toxicity and harm potential

 

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens

The toxicity and long-term health effects of recreational 4-HO-MiPT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 4-HO-MiPT is a research chemical with very little history of human usage.

Anecdotal evidence from those have tried 4-HO-MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

4-HO-MiPT is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 4-HO-MiPT is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 4-HO-MiPT presents cross-tolerance with all psychedelics, meaning that after the consumption of 4-HO-MiPT all psychedelics will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Legal status

 

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Brazil: As of August 21, 2018, 4-HO-MiPT has been added to Portaria SVS/MS nº 344. Possession, distribution and use of this substance is now considered illegal.[7]
  • Germany: 4-HO-MiPT is controlled under the NpSG[8] (New Psychoactive Substances Act) as of July 18, 2019.[9] Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable.[10][11] The legislator considers it possible that orders of 4-HO-MiPT are punishable as an incitement to place it on the market.[12]
  • Japan: 4-HO-MiPT is a controlled substance in Japan effective March 25th, 2015.[13]
  • Poland: 4-HO-MiPT is a NPS class drug in Poland, making it illegal to possess or distribute.[14]
  • Sweden: 4-HO-MiPT is classified as a health hazard under the act Lagen om förbud mot vissa hälsofarliga varor (translated as the "Act on the Prohibition of Certain Goods Dangerous to Health") as of November 1, 2005, making it illegal to sell or possess.[15]
  • Switzerland: 4-HO-MiPT is a controlled substance specifically named under Verzeichnis E.[16]
  • United Kingdom: 4-HO-MiPT is a Class A drug in the United Kingdom as a result of the tryptamine catch-all clause.[17]
  • United States: 4-HO-MiPT is unscheduled in the United States. It may be considered an analogue of psilocin (4-HO-DMT) which is a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.[citation needed]

See also

External links

Discussion

References

  1. ↑ Alexander Shulgin (1980). Pharmacology Notes II (The Shulgin Lab Books) (PDF). Lafayette, CA: Erowid. p. 312. 
  2. ↑ 2.0 2.1 Shulgin, Alexander; Shulgin, Ann (1997). "#22. 4-HO-MiPT". TiHKAL: The Continuation. United States: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252. 
  3. ↑ Repke, D. B.; Ferguson, W. J.; Bates, D. K. (1981). "Psilocin analogs II. Synthesis of 3-[2-(dialkylamino)ethyl]-, 3-[2-(N-methyl-N-alkylamino)ethyl]-, and 3-[2-(cycloalkylamino)ethyl]indol-4-ols". Journal of Heterocyclic Chemistry. 18 (1): 175–179. doi:10.1002/jhet.5570180131. ISSN 0022-152X. OCLC 1783072. 
  4. ↑ Repke, D. B.; Grotjahn, D. B.; Shulgin, A. T. (1985). "Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents". Journal of Medicinal Chemistry. 28 (7): 892–896. doi:10.1021/jm00145a007. eISSN 1520-4804. ISSN 0022-2623. OCLC 39480771. PMID 4009612. 
  5. ↑ "4-HO-MiPT". Psychedelic Science Review. 6 January 2020.
  6. ↑ Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  7. ↑ "Lista de substâncias sujeitas a controle especial no Brasil" (in Portuguese). Agência Nacional de Vigilância Sanitária (ANVISA) [Brazilian Health Regulatory Agency]. Retrieved August 27, 2020. 
  8. ↑ "Anlage NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  9. ↑ "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. ISSN 0341-1095. 
  10. ↑ "§ 4 NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  11. ↑ "§ 3 NpSG" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  12. ↑ "Gesetzentwurf der Bundesregierung: Entwurf eines Gesetzes zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Deutscher Bundestag. May 30, 2016. p. 20. Drucksache 18/8579. 
  13. ↑ "危険ドラッグの成分１６物質を新たに指定薬物に指定" (in Japanese). 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)]. Retrieved May 2, 2022. 
  14. ↑ "Rozporządzenie Ministra zdrowia z dnia 21 sierpnia 2019 r. zmieniające rozporządzenie w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych" (PDF) (in Polish). Sejm Rzeczypospolitej Polskiej [Sejm of the Republic of Poland]. August 21, 2019. 
  15. ↑ "Svensk författningssamling Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor" (PDF) (in Swedish) (published October 18, 2005). October 6, 2005. SFS 2005:733. 
  16. ↑ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  17. ↑ "Schedule 2: Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved August 20, 2020. 


Retrieved from ‘https://psychonautwiki.org/w/index.php?title=4-HO-MiPT&oldid=151045’